IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17

Rheumatology

Volumn 47, Issue 11, 2008, Pages 1635-1640

  Hashizume, M ^a   Hayakawa, N ^a   Mihara, M ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Fibroblast like synoviocytes; Interleukin 1; Interleukin 17; Interleukin 6; Janus kinase signal transducer and activator of transcription; Mitogen activated protein kinase; Receptor activator of nuclear factor B ligand; Soluble IL 6 receptor; Tocilizumab; Tumour necrosis factor

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOCLAST DIFFERENTIATION FACTOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYNOVIOCYTE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; FLAVONOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-6; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SESQUITERPENES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STIMULATION, CHEMICAL; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54449101331     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken363     Document Type: Article

References (31)

1. Fujikawa Y, Shingu M, Torisu T, Itonaga I, Masumi S. Bone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synovium. Br J Rheumatol 1996;35:213-7.
2. Gravallese EM, Manning C, Tsay A et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
3. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
4. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
5. Dougall WC, Glaccium M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-24.
6. Li J, Sarosi I, Yen XQ et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-71.
7. Takayanagi H, Iizuka H, Juji T et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
8. Madson KL, Moore TL, Lawrence JM 3rd, Osborn TG. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatol 1994;21:2359-63.
9. Kutukculer N, Caglayan S, Aydogdu F. Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters. Clin Rheumatol 1998;17:288-92.
10. Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
11. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1 beta and tumor necrosis factor-alpha, but not intedeukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-9.
12. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 1999;274:19301-8.
13. Sobota R, Szwed M, Kasza A, Bugno M, Kordula T. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem Biophys Res Commun 2000;267:329-33.
14. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.
15. Legendre F, Dudhia J, Pujol JP, Bogdanowicz B. JAK/STAT but not ERK1/ ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 2003; 278:2903-12.
16. Kubota A, Hasegawa K, Suguro T, Koshihara Y. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. J Rheumatol 2004;31:426-35.
17. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995;34:321-5.
18. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282-90.
19. Beklen A, Ainola M, Hukkanen M, Gürgan C, Sorsa T, Konttinen YT. MMPs, IL-1, and TNF are regulated by IL-17 in periodontitis. J Dent Res 2007;86:347-51.
20. Furst DE. Anakinra: Review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 2004;26:1960-75.
21. Kotake S, Sato K, Kim KJ et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88-95.
22. Desgeorges A, Gabay C, Silacci P et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 1997;24:1510-6.
23. Müllberg J, Oberthür W, Lottspelch F et al. The soluble human IL-6 reoeptor. Mutational characterization of the proteolytic cleavage site. J Immunol 1994; 152:4958-68.
24. Horiuchi S, Koyanagi Y, Zhou Y et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 1994;24:1945-8.
25. Franchimont N, Lambert C, Huynen P et al. Interleukin-6 receptor shedding is enhanced by interleukin-1 beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells. Arthritis Rheum 2005;52:84-93.
26. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990;63:1149-57.
27. Takayanagi H, Kim S, Koga T et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901.
28. Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: A model of the cytokine system. Cytokine Growth Factor Rev 1997;8:241-52.
29. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56.
30. Hibi M, Hirano T. Gab-family adapter molecules in signal transduction of cytokine and growth factor receptors, and T and B cell antigen receptors. Leuk Lymphoma 2000;37:299-307.
31. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.